Gastric Cancer pp 157-162 | Cite as

Biological Markers for Staging of Gastric Cancer?

  • B. Heymer
  • A. Quentmeier
Conference paper


In the strict sense of the term, biological markers of tumors are substances — such as enzymes, hormones, or antigens — which are produced by the respective tumor and released into the body fluids where they may be detected. However, in a broader sense, the term includes characteristic reactions of the organism against the tumor, such as the formation of antibodies or cellular immune factors to tumor antigens. There are several examples of the successful application of such biological markers for the diagnosis or postoperative follow-up of human malignancies: the determination of AFP in liver carcinoma [13], of β-HCG in chorionic carcinoma [15], of CEA in colon carcinoma [14], and of EBV-antibodies in Burkitt lymphoma [9].


Gastric Cancer Biological Marker Tissue Polypeptide Antigen Gastric Cancer Stage Migration Inhibition Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Björklund, B.: Tissue polypeptide antigen; review of physical chemistry and clinical application. In: Clinical application of carcinoembryonic antigen assay. Krebs, B. P., Lalanne, C. M., Schneider, M. (eds.), pp. 59–63. Amsterdam, Oxford: Excerpta Medica 1978Google Scholar
  2. 2.
    Bone, G., Lauder, I.: Cellular immunity, peripheral blood lymphocyte count and pathological staging of tumours in the gastrointestinal tract. Cancer 30, 215–221 (1974)CrossRefGoogle Scholar
  3. 3.
    Bone, G., Appleton, D. R., Venables, C. W.: Cutaneous delayed hypersensitivity responses to 2–4 dinitrochlorobenzene — a prognostic guide in malignant disease. Br. J. Surg. 60, 906 (1973)PubMedCrossRefGoogle Scholar
  4. 4..
    Costanza, M. E., Das, S., Nathanson, L., Rule, A., Schwartz, R. S.: Carcinoembryonic antigen. Cancer 33, 583–590(1974)PubMedCrossRefGoogle Scholar
  5. 5.
    Daver, A., Wafflart, J., Ben Boueli, A., Minier, J. F., Larra, F.: β2-microglobulin (β2-micro) and carcinoembryonic antigen (CEA) in intestinal cancers — a correlation with stage of disease. In: Clinical application of carcinoembryonic antigen assay. Krebs, B. P., Lalanne, C. M., Schneider, M. (eds.), pp. 460–465. Amsterdam, Oxford: Excerpta Medica 1978Google Scholar
  6. 6.
    Fuks, A., Banjo, Ch., Shuster, J., Freedmann, S. O., Gold, P.: Carcinoembryonic antigen (CEA): Molecular biology and clinical significance. Biochem. Biophys. Acta 417, 123–152 (1974)Google Scholar
  7. 7.
    Hamasaki, K.: Cell-mediated immunity against digestive organ cancers: leukocyte migration inhibitory factor activity as an immunological parameter. Acta Med. Okayama 31, 147–159 (1977)PubMedGoogle Scholar
  8. 8.
    Hansen, H. J., Snyder, J. J., Miller, E., Vandevoorde, J. P., Miller, O. N., Hines, L. R., Burns, J. J.: Carcinoembryonic antigen (CEA) assay. Hum. Pathol. 5, 139–147 (1974)PubMedCrossRefGoogle Scholar
  9. 9.
    Henle, W., Henle, G., Gunvin, P., Klein, G., Clifford, P., Single, S.: Patterns of antibodies to Epstein-Barr-Virus induced early antigens in Burkitt’s lymphoma. Comparison of dying patients with long-term survivors. J. Natl. Cancer Inst. 50, 1163 (1973)PubMedGoogle Scholar
  10. 10.
    Johnson, M. W., Maibach, H. I., Salmon, S. E.: Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response? N. Engl. J. Med. 284, 1255–1257 (1971)PubMedCrossRefGoogle Scholar
  11. 11.
    Klein, G.: Tumour antigens. Biochem. Soc. Trans. 4, 8–9 (1976)PubMedGoogle Scholar
  12. 12.
    Lamerz, R., Fateh-Moghadam, A.: Carcinofetale Antigene. III. Andere Carcinofetale Antigene. Klin. Wochenschr. 53, 403–417 (1975)PubMedCrossRefGoogle Scholar
  13. 13.
    Lamerz, R., Fateh-Moghadam, A.: Carcinofetale Antigene. I. Alpha-Fetoprotein. Klin. Wochenschr. 53, 147–169 (1975)PubMedCrossRefGoogle Scholar
  14. 14.
    Lehmann, F. G.: Serologische Tumordiagnostik. Internist (Berlin) 16, 214–222 (1975)Google Scholar
  15. 15.
    Lehmann, F. G.: Kongreßbericht: 5th meeting of the International Research Group of Carcino-Embryonic Proteins (IRGCP). Inn. Med. 4, 388–390 (1977)Google Scholar
  16. 16.
    Gerfo, P., Pennington, G.: Current status of carcinoembryonic antigen. Prog. Clin. Cancer 6, 65–71(1975)PubMedGoogle Scholar
  17. 17.
    Martin, E. W., James, K. K., Hurtubise, P. E., Catalano, P., Minton, J. P.: The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer 39, 440–446(1977)PubMedCrossRefGoogle Scholar
  18. 18.
    Pant, K. D., Dahlman, H. L., Goldenberg, D. M.: A putatively new antigen (CSAp) associated with gastrointestinal and ovarian neoplasia. Immunol. Commun. 6, 411–421 (1977)PubMedGoogle Scholar
  19. 19.
    Pappas, A., Scheurlen, P. G.: Lymphocyte transformation in malignant diseases. Communication II: Results in reticulo- and lymphoproliferative diseases as well as in carcinomas. In: Applied tumor immunology. Götz, H., Bücherl, E. S. (eds.), pp. 305–331. Berlin, New York: de Gruyter 1975Google Scholar
  20. 20.
    Rapp, W., Matzku, S., Wurster, K. H.: Stand der Isolierung CEA-ähnlicher Substanzen aus menschlicher Tumormagenschleimhaut. In: Tumorantigene in der Gastroenterologie. Lehmann, F. G. (ed.), pp. 39–43. Gräfelfing: Demeter 1976Google Scholar
  21. 21.
    Staab, H. J., Anderer, F. A., Stumpf, E., Fischer, R.: Second-look surgery of gastrointestinal carcinoma and the potential value of CEA monitoring. In: Clinical application of carcinoembryonic antigen assay. Krebs, B. P., Lalanne, C. M., Schneider, M. (eds.), pp. 94–100. Amsterdam, Oxford: Excerpta Medica 1978Google Scholar
  22. 22.
    Stillman, A., Zamcheck, N.: Recent advances in immunologic diagnosis of digestive tract cancer. Digest. Dis. 15, 1003–1018 (1970)CrossRefGoogle Scholar
  23. 23.
    Trejdosiewicz, L. K., Dykes, P. W.: And-tumour monocyte activity in gastric carcinoma patients receiving intra-tumoral C. parvum. In: The macrophage and cancer. James K., McBride, B., Stuart, A. (eds.), pp. 426–437. Edinburgh: Econoprint 1977Google Scholar
  24. 24.
    Vuento, M., Ruoslahti, E., Pihko, H., Svenberg, T., Ihamäki, T., Siurala, M.: Carcinoembryonic antigen-like substance in gastric juice. Immunochemistry 13, 313–316 (1976)PubMedCrossRefGoogle Scholar
  25. 25.
    Zöller, M., Matzku, S., Lernhardt, W., Schulz, U.: Evaluation of different antigen sources for leukocyte migration testing of gastrointestinal cancer patients. In: Clinical application of carcinoembryonic antigen assay. Krebs, B. P., Lalanne, C. M., Schneider, M. (eds.), pp. 155–160. Amsterdam, Oxford: Excerpta Medica 1978Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1979

Authors and Affiliations

  • B. Heymer
  • A. Quentmeier

There are no affiliations available

Personalised recommendations